Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Other ORP type
Data sources: ZENODO
addClaim

What evidence supports biological therapy, aside from anti-TNF therapy, for ileal Crohn's disease with perianal disease?

Authors: Tripdatabase;

What evidence supports biological therapy, aside from anti-TNF therapy, for ileal Crohn's disease with perianal disease?

Abstract

While anti-TNF therapy is a mainstay for Crohn's disease, other biological treatments such as ustekinumab, guselkumab, mirikizumab, and upadacitinib show promise for Ileal Crohn's disease with perianal involvement.

Powered by OpenAIRE graph
Found an issue? Give us feedback